U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C42H72O14
Molecular Weight 801.0127
Optical Activity UNSPECIFIED
Defined Stereocenters 21 / 21
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GINSENOSIDE RG1

SMILES

CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]2CC[C@]3(C)[C@@H]2[C@H](O)C[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5[C@H](C[C@@]34C)O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O

InChI

InChIKey=YURJSTAIMNSZAE-HHNZYBFYSA-N
InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,56-37-34(52)32(50)30(48)25(19-44)55-37)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23-,24+,25+,26+,27-,28-,29+,30+,31-,32-,33+,34+,35-,36+,37-,39+,40+,41+,42-/m0/s1

HIDE SMILES / InChI

Molecular Formula C42H72O14
Molecular Weight 801.0127
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 21 / 21
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rg1/ https://www.ncbi.nlm.nih.gov/pubmed/15663889

Ginsenoside Rg1 is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-inflammatory, neuroprotective, anti-aging, anti-fibrotic, anticancer, antithrombotic, anti-allergic, immunomodulatory, cardioprotective, and pro-angiogenic activities. Ginsenoside Rg1 appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity. In an animal model of aging, ginsenoside Rg1 prevents decreases in cognitive capacity and neurogenesis, and suppresses astrocyte activation and production of TNF-α, IL-6, and IL-1β; it also increases activity of telomerase, glutathione peroxidase, and superoxide dismutase. In other animal models, ginsenoside Rg1 decreases levels of ALT, AST, LDH, and ALP, inhibiting inflammation and hepatic stellate cell activation, decreasing fibrosis. Additionally, ginsenoside Rg1 suppresses JAK2/STAT5 signaling in leukemia cells, upregulates expression of Bax and caspase 3, downregulates expression of Bcl-2, induces apoptosis, and inhibits cell proliferation. This compound also inhibits platelet aggregation, fibrinogen binding, P-selection expression, platelet adhesion, and ERK activation, increasing time to occlusion in vivo. Ginsenoside Rg1 inhibits left ventricular hypertrophy and increases expression of HIF-1α and VEGF in other animal models. This compound also decreases serum histamine, IgE, and IgG and suppresses infiltration of eosinophils and mast cells in animal models of allergic rhinitis. Ginsenoside Rg1 is one of the major components of Korean Red Ginseng, marketed in Korea. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for: • Alzheimer's disease. Evidence shows that taking Panax ginseng root daily for 12 weeks can improve mental performance in people with Alzheimer's disease. • Lung disease called chronic obstructive pulmonary disease (COPD). Taking Panax ginseng by mouth seems to improve lung function and some symptoms of COPD. • Mental function. Taking Panax ginseng by mouth might improve abstract thinking, mental arithmetic skills, and reaction times in healthy, middle-aged people but not in young adults. Panax ginseng alone does not seem to improve memory. But there is some evidence that a combination of Panax ginseng and ginkgo leaf extract can improve memory in otherwise healthy people between the ages of 38 and 66. • Erectile dysfunction (ED). Taking Panax ginseng by mouth seems to improve sexual function in men with erectile dysfunction. • Flu. Taking a specific Panax ginseng by mouth appears to reduce the risk of getting a cold or the flu. But, taking Panax ginseng does not seem to reduce flu symptoms or the length of the illness. • Multiple sclerosis-related fatigue. Taking Panax ginseng daily for 3 months reduces feelings of tiredness and improves quality of life in females with MS. • Premature ejaculation. Applying a cream containing Panax ginseng, angelica root, Cistanches deserticola, Zanthoxyl species, torlidis seed, clover flower, asiasari root, cinnamon bark, and toad venom (SS Cream) to the penis one hour before intercourse and washing off immediately before intercourse seems to help prevent premature ejaculation.

CNS Activity

Curator's Comment: Ginsenoside Rg1 can go across the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB), and then immediately distribute to learning and memory-related regions in brain, which may lead to rapid pharmacological onset

Approval Year

PubMed

PubMed

TitleDatePubMed
Effects of ginsenoside on G protein-coupled inwardly rectifying K+ channel activity expressed in Xenopus oocytes.
2003-05-09
SEK1-dependent JNK1 activation prolongs cell survival during G-Rh2-induced apoptosis.
2003-05-02
Modulation of G protein alpha-subunit mRNA levels in discrete rat brain regions by cerebroventricular infusion of ginsenoside Rc and Rg1.
2003-05
In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes.
2003-04-23
Growth and ginsenoside production in hairy root cultures of Panax ginseng using a novel bioreactor.
2003-04
Enzymatic preparation of ginsenosides Rg2, Rh1, and F1.
2003-04
Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion.
2003-03-12
A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells.
2003-03
Induction of NGF synthesis in astrocytes by onjisaponins of Polygala tenuifolia, constituents of kampo (Japanese herbal) medicine, Ninjin-yoei-to.
2003-03
Enzymatic preparation of ginsenosides Rg2, Rh1, and F1 from protopanaxatriol-type ginseng saponin mixture.
2003-03
Effects of ginsenoside Rd and decursinol on the neurotoxic responses induced by kainic acid in mice.
2003-03
Effect of ginsenoside Rb1 on long-term potentiation in the dentate gyrus of anaesthetized rats.
2003-03
Effects of ginsenoside Rg2 on the 5-HT3A receptor-mediated ion current in Xenopus oocytes.
2003-02-28
Effects of ginsenosides on glycine receptor alpha1 channels expressed in Xenopus oocytes.
2003-02-28
Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats.
2003-02
Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.
2003-02
Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2.
2003-02
Adjuvant effect of ginseng extracts on the immune responses to immunisation against Staphylococcus aureus in dairy cattle.
2003-01-10
Ginsenoside Rf potentiates U-50,488H-induced analgesia and inhibits tolerance to its analgesia in mice.
2003-01-03
Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3).
2003-01-01
Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells.
2003-01
Ginsenoside Rc and Re stimulate c-fos expression in MCF-7 human breast carcinoma cells.
2003-01
Effects of ginsenosides on GABA(A) receptor channels expressed in Xenopus oocytes.
2003-01
[Effects of panax notoginseng saponins on the expression of tumor necrosis factor alpha and secretion phospholipase A2 in rats with liver fibrosis].
2003-01
Components of Panax ginseng that improve accelerated small intestinal transit.
2003-01
Effects of Ginsenoside Rb1 on proliferation of Schwann cells in culture.
2002-12
The nootropic properties of ginseng saponin Rb1 are linked to effects on anxiety.
2002-11-19
Ginsenoside Rb1 enhances peripheral nerve regeneration across wide gaps in silicone rubber chambers.
2002-11
Preparation of the traditional Chinese medicine compound recipe heart-protecting musk pH-dependent gradient-release pellets.
2002-11
Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line.
2002-10-01
[Studies on heart-protecting musk pH-dependent gradient-release pellets].
2002-10
Dammarane-type Saponins from Panax japonicus and their neurite outgrowth activity in SK-N-SH cells.
2002-09
Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons.
2002-09
Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons.
2002-08-16
[Effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice].
2002-08
Three new dammarane glycosides from heat processed ginseng.
2002-08
Extractable polysaccharides of Panax quinquefolius L. (North American ginseng) root stimulate TNFalpha production by alveolar macrophages.
2002-07
[Possible mechanisms of the protective effect of ginsenoside Rg1 on apoptosis in substantia nigra neurons].
2002-04
[Saponins with low sugar chain from the leaves of Panax notoginseng (Burk) F. H. Chen].
2002-03
Effect of ginsenoside Re on cardiomyocyte apoptosis and expression of Bcl-2/Bax gene after ischemia and reperfusion in rats.
2002
Effect of ginsenoside-Rb1 on cardiomyocyte apoptosis after ischemia and reperfusion in rats.
2002
[Effect of Rg2 on hemodynamics of hemorrhagic shock and its antioxidation in dogs].
2001-08
[Metabolism of ginsenoside Rb1 and panaxadiol saponins by fungi].
2001-08
[HPLC fingerprints identification of Panax ginseng C. A. Mey., P. quinquefolin L. and P. notoginseng (Burk. F. H. Chen)].
2001-07
[Possible mechanism of the protective effects of ginsenoside Rg1 on apoptosis in PC12 cells].
2001-06
[Clinical study on effect of ginsenoside in inducing rectal cancer cell apoptosis].
2001-04
[Pharmacokinetic studies of 20(R)-ginsenoside RG3 in human volunteers].
2001-03
[Research on the transformation of ginsenoside Rg1 by intestinal flora].
2001-03
[Effect of ginsenoside Rg1 on learning and memory impairment induced by beta-amyloid peptide(25-35) and its mechanism of action].
2001-01
[Studies on saponin accumulative in regularities Panax notoginseng (Burk) F. H. Chen].
2001-01
Patents

Sample Use Guides

Vascular Dementia:1 Fufangdanshen tablet contains ginsenoside Rg1 2.73mg, as well as tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg. 3 tablets per time, 3 times per day for 24 weeks
Route of Administration: Oral
Pre-treatment with Ginsenoside Rg1 (0.1-10 uM) attenuated hydrogen peroxide (H2O2)-induced neuronal apoptosis and oxidative stress through reducing the intracellular reactive oxygen species (ROS) production and methane dicarboxylic aldehyde (MDA) level.
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:01:08 GMT 2025
Edited
by admin
on Mon Mar 31 22:01:08 GMT 2025
Record UNII
PJ788634QY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GINSENOSIDE RG1
USP-RS  
INCI  
Official Name English
(3.BETA.,6.ALPHA.,12.BETA.)-3,12-DIHYDROXYDAMMAR-24-ENE-6,20- DIYLBIS(.BETA.-D-GLUCOPYRANOSIDE)
Preferred Name English
GINSENOSIDE RG1 (CONSTITUENT OF AMERICAN GINSENG, ASIAN GINSENG, AND TIENCHI GINSENG) [DSC]
Common Name English
.BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,6.ALPHA.,12.BETA.)-3,12- DIHYDROXY DAMMAR-24-ENE-6,20-DIYLBIS-
Systematic Name English
(6)-.BETA.-D-GLUCOPYRANOSYL-(20)-.BETA.-D-GLUCOPYRANOSYL-20S- PROTOPANAXATRIOL
Common Name English
Ginsenoside Rg1 [WHO-DD]
Common Name English
GINSENOSIDE A2
Common Name English
PANAXOSIDE A
Common Name English
.BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,6.ALPHA.,12.BETA.)-3,12-DIHYDROXYDAMMAR-24-ENE-6,20-DIYL BIS-
Systematic Name English
SANCHINOSIDE C1
Common Name English
GINSENOSIDE RG1 [USP-RS]
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID70945111
Created by admin on Mon Mar 31 22:01:08 GMT 2025 , Edited by admin on Mon Mar 31 22:01:08 GMT 2025
PRIMARY
FDA UNII
PJ788634QY
Created by admin on Mon Mar 31 22:01:08 GMT 2025 , Edited by admin on Mon Mar 31 22:01:08 GMT 2025
PRIMARY
ECHA (EC/EINECS)
244-989-9
Created by admin on Mon Mar 31 22:01:08 GMT 2025 , Edited by admin on Mon Mar 31 22:01:08 GMT 2025
PRIMARY
CAS
22427-39-0
Created by admin on Mon Mar 31 22:01:08 GMT 2025 , Edited by admin on Mon Mar 31 22:01:08 GMT 2025
PRIMARY
PUBCHEM
441923
Created by admin on Mon Mar 31 22:01:08 GMT 2025 , Edited by admin on Mon Mar 31 22:01:08 GMT 2025
PRIMARY
DRUG BANK
DB06750
Created by admin on Mon Mar 31 22:01:08 GMT 2025 , Edited by admin on Mon Mar 31 22:01:08 GMT 2025
PRIMARY
CHEBI
67987
Created by admin on Mon Mar 31 22:01:08 GMT 2025 , Edited by admin on Mon Mar 31 22:01:08 GMT 2025
PRIMARY
RS_ITEM_NUM
1291672
Created by admin on Mon Mar 31 22:01:08 GMT 2025 , Edited by admin on Mon Mar 31 22:01:08 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT